Lantheus (NASDAQ:LNTH) Price Target Raised to $115.00

Lantheus (NASDAQ:LNTH) had its price target hoisted by analysts at Citizens Jmp from $85.00 to $115.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the medical equipment provider’s stock. Citizens Jmp’s price objective indicates a potential upside of 22.53% from the stock’s current price.

LNTH has been the subject of several other research reports. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a report on Friday, May 1st. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Jefferies Financial Group restated a “buy” rating and set a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Truist Financial upped their price target on shares of Lantheus from $89.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $97.29.

Lantheus Stock Performance

NASDAQ:LNTH traded up $2.86 on Friday, hitting $93.86. The company’s stock had a trading volume of 523,423 shares, compared to its average volume of 914,183. Lantheus has a one year low of $47.25 and a one year high of $94.00. The firm has a market capitalization of $6.11 billion, a P/E ratio of 27.87 and a beta of -0.08. The stock has a fifty day moving average of $79.69 and a two-hundred day moving average of $68.87. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus will post 4.26 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after acquiring an additional 115,338 shares in the last quarter. M&T Bank Corp acquired a new stake in Lantheus in the 4th quarter worth about $370,950,000. Farallon Capital Management LLC boosted its holdings in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares during the period. Reinhart Partners LLC. boosted its holdings in Lantheus by 15.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after purchasing an additional 44,374 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Key Stories Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q1 earnings beat — Lantheus reported $1.46 EPS vs. $1.25 consensus and revenue of $377.3M vs. $354.5M expected, underscoring operational strength and supporting the rally. MarketBeat Q1 Coverage
• Positive Sentiment: FY?2026 EPS guidance raised — management set FY?2026 EPS at $5.00–$5.25 vs. consensus ~4.99, which investors view as bullish for near?term earnings power. Press Release
• Positive Sentiment: Sell?side boost — Mizuho raised its price target from $95 to $100 and moved to an “outperform” rating, providing incremental analyst validation for the stock’s upside. Benzinga
• Positive Sentiment: Revenue surprise & incremental coverage — media reports (Yahoo, Chron) highlighted the sales surprise and operational snapshot, reinforcing the market’s positive reaction to the quarter. Yahoo – Sales Surprise
• Neutral Sentiment: Valuation and catalysts analysis — recent writeups review Lantheus’ valuation after the beat and flag upcoming FDA approval catalysts as potential medium?term drivers; useful context but not a direct catalyst. Yahoo – Valuation Check
• Neutral Sentiment: Earnings call transcript available — full call transcript provides detail on drivers, margins (net margin ~15.2%) and ROE (~30.8%) for investors doing deeper diligence. Seeking Alpha Transcript
• Negative Sentiment: Revenue guidance range is mixed — management set FY revenue guidance at $1.4–$1.5B versus a ~$1.5B consensus; the lower end leaves some revenue risk if growth slows, which could temper upside. Press Release

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.